Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiofarmBSE:BIO +1.88%69 FCF Margin % is 28.32% as of Jun. 2026, which is 112% above its 10-year median of 13.34. GuruFocus rates BSE:BIO with a GF Score™ of 69/100 and a GF Value™ of lei0.83 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 959 Drug Manufacturers companies, Biofarm ranks better than 86.55% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biofarm's Free Cash Flow for the
three
months ended in Jun. 2026 was lei12.8 Mil. Biofarm's Revenue for the
three
months ended in Jun. 2026 was lei45.3 Mil. Therefore, Biofarm's FCF Margin % for the quarter that ended in Jun. 2026 was 28.32%.
The historical data trend for Biofarm's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:BIO vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biofarm's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (BSE:BIO) has a FCF Margin % of 28.32% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biofarm and its competitors. This is 112% above median its historical median of 13.34. According to the industry distribution chart, Biofarm ranks #129 out of 959 companies in the Drug Manufacturers industry, placing it in the top 13.5%.
Is Biofarm's FCF Margin % too high?
Biofarm's current FCF Margin % of 28.32% is 112% above median its 10-year median of 13.34. The Drug Manufacturers industry median FCF Margin % is 2.45. Biofarm's value of 28.32% is 1055.9% above this industry median. Based on the distribution chart, Biofarm ranks #129 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofarm has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #129 out of 959 companies for FCF Margin %. This places Biofarm in the top 14% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Biofarm's value of 28.32% is 1055.9% above this benchmark. While the company's 10-year median is 13.34 vs. the industry median of 2.45, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current FCF Margin % of 28.32% is 1055.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current FCF Margin % is 28.32%, which is 112% above median its own 10-year median of 13.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.83, compared to a current price of lei1.36 — trading 63.3% above its estimated fair value. The current FCF Margin % is 28.32%, which is 112% above median its 10-year median of 13.34 and 1055.9% above the Drug Manufacturers industry median of 2.45. Biofarm's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current FCF Margin % is 28.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (BSE:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei1.36 is trading 63.3% above its estimated GF Value™ of lei0.83.
GuruFocus considers Biofarm to be Significantly Overvalued.
Key valuation signals for BSE:BIO:
FCF Margin %: 28.32% (112% above median its 10-year median of 13.34)
GF Value™: lei0.83 vs. price of lei1.36 (63.3% above fair value)
Industry Position: 1055.9% above the Drug Manufacturers median (#129 of 959)
No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score
Get the complete analysis for BSE:BIO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:BIO has been successfully added to your 
